LIDEX
LOE ApproachingNDATOPICALSOLUTION
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LIDEX by Alvogen is clinical pharmacology: mechanism of action: lidexagel® 5% gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1984.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX is a topical lidocaine 5% gel solution that delivers local anesthetic action by stabilizing neuronal membranes and inhibiting ionic fluxes required for nerve impulse conduction. The mild acidic vehicle lowers pH to protect against alkaline irritants and promote healing. It is used for topical local anesthesia on mucous membranes and affected skin areas.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team size and hiring activity likely minimal as focus shifts to generic transition strategy.
Mechanism of Action
CLINICAL PHARMACOLOGY: Mechanism of Action: LidexaGel® 5% Gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. A mild acidic vehicle lowers…
Worked on LIDEX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.